Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411743 | 0.82 | BCHE (0.43) | BCHEACHEMPOHTR3AKCNH2 | |
| SCHEMBL27969337 | 0.82 | BCHE (0.43) | BCHEACHEMPOHTR1ASLC6A2 | |
| SCHEMBL23411483 | 0.82 | MPO (0.46) | BCHEACHEMPOHTR1ASLC6A2 | |
| SCHEMBL23411589 | 0.77 | BCHE (0.36) | HTR2CBCHEACHEMPOSLC6A2 | |
| SCHEMBL4308323 | 0.77 | TOP2A (0.51) | HTR2CUSP2HTR3AKCNH2LMNA | |
| SCHEMBL20135544 | 0.77 | HTR2C (0.46) | HTR2CBCHEACHEUSP2MPO | |
| SCHEMBL373400 | 0.75 | MPO (0.54) | BCHEACHEUSP2MPOKCNH2 | |
| SCHEMBL23411036 | 0.71 | LMNA (0.49) | BCHEACHEUSP2MPOKCNH2 | |
| SCHEMBL2708939 | 0.71 | MPO (0.59) | HTR2CMPOPOLB | |
| SCHEMBL29891587 | 0.71 | LMNA (0.49) | BCHEACHEUSP2MPOKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| CN-107922347-A | New imide derivative and its purposes as medicine | 田边三菱制药株式会社 | 2018-04-17 | — | — | CN | disclosed |
| US-6303627-B1 | FOR THERAPY OF PHYSIOLOGICAL AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-1999065487-A1 | INHIBITORS OF SEROTONIN REUPTAKE | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0965587-A1 | Tetrahydropyridinyl- and piperidinyl Inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | HTR2C 3534/4885BCHE 3588/4885ACHE 2728/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | HTR2C 3675/4885BCHE 3598/4885ACHE 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.